Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1124982

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 24 April 2019 to Question 244142 on Cannabis: Medical Treatments, whether his Department defines Naboline as a cannabis imitating rather than cannabis derived product.
tabling member constituency	Cardiff Central
tabling member printed	Jo Stevens
uin	251364
answer	answer is ministerial correction date of answer 13/05/2019 answer text <p>The Department recognises both Nabilone and Sativex as licensed cannabis-based medicines. Neither, however, falls within the scope of the definition of a ‘cannabis-based product for medicinal use’ under the recent change to the law.</p><p>Nabilone is a synthetic non-natural cannabinoid that mimics delta-9-tetrahydrocannabinol (THC). It was issued a marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA), for nausea and vomiting caused by chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments, on 14 February 1995. There are no restrictions on its prescribing in the National Health Service.</p><p>Sativex (nabiximols) is an oromucosal spray that contains THC and cannabidiol (CBD). It was issued a marketing authorisation by the MHRA, for treatment of spasticity in people with multiple sclerosis who have failed to respond adequately to other anti-spasticity medications, on 16 June 2010. In October 2014, the National Institute for Health and Care Excellence recommended that Sativex is not offered for use on the NHS because it is not a cost-effective treatment. Sativex therefore is not routinely prescribed on the NHS, and can only be prescribed for an individual patient, where local governance and funding arrangements allow for this.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 251366 question first answered 13/05/2019 15:38:24 answering member 4455 label Biography information for Seema Kennedy
tabling member	4425 label Biography information for Jo Stevens

1124983

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 24 April 2019 to Question 244142 on Cannabis: Medical Treatments, whether his Department is aware of any instances of (a) CBD and (b) THC being prescribed by the NHS since 1 January 2019.
tabling member constituency	Cardiff Central
tabling member printed	Jo Stevens
uin	251365
answer	answer is ministerial correction date of answer 13/05/2019 answer text <p>The published data shows that the following number of items of Nabilone (a synthetic product which mimics tetrahydrocannabinol (THC)) and Sativex (a product containing natural THC and cannabidiol (CBD)) were dispensed in January and February 2019.</p><p> </p><table><tbody><tr><td><p> </p></td><td colspan="2"><p>Number of prescription items</p></td></tr><tr><td><p> </p></td><td><p>January 2019</p></td><td><p>February 2019</p></td></tr><tr><td><p>Nabilone</p></td><td><p>44</p></td><td><p>36</p></td></tr><tr><td><p>Sativex</p></td><td><p>167</p></td><td><p>159</p></td></tr></tbody></table><p> </p><p>Data, from the NHS Business Services Authority for January and February 2019, suggest that three National Health Service prescriptions were dispensed for unlicensed cannabis-based products for medicinal use in primary care in England during this time. Additionally, the NHS Business Services Authority data report that 10 private prescriptions were dispensed for unlicensed cannabis-based products for medicinal use in January and February 2019.</p><p> </p><p>Unlike NHS primary care where all dispensed prescriptions are processed centrally, this is not the case for secondary care. This information is collected by a third party and not routinely published.</p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 13/05/2019 16:07:00 answering member 4455 label Biography information for Seema Kennedy
tabling member	4425 label Biography information for Jo Stevens

1124984

registered interest
date	07/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 24 April 2019 to Question 244142 on Cannabis: Medical Treatments, when (a) Naboline and (b) Savitex were first made available to prescribe on the NHS.
tabling member constituency	Cardiff Central
tabling member printed	Jo Stevens
uin	251366
answer	answer is ministerial correction date of answer 13/05/2019 answer text <p>The Department recognises both Nabilone and Sativex as licensed cannabis-based medicines. Neither, however, falls within the scope of the definition of a ‘cannabis-based product for medicinal use’ under the recent change to the law.</p><p>Nabilone is a synthetic non-natural cannabinoid that mimics delta-9-tetrahydrocannabinol (THC). It was issued a marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA), for nausea and vomiting caused by chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments, on 14 February 1995. There are no restrictions on its prescribing in the National Health Service.</p><p>Sativex (nabiximols) is an oromucosal spray that contains THC and cannabidiol (CBD). It was issued a marketing authorisation by the MHRA, for treatment of spasticity in people with multiple sclerosis who have failed to respond adequately to other anti-spasticity medications, on 16 June 2010. In October 2014, the National Institute for Health and Care Excellence recommended that Sativex is not offered for use on the NHS because it is not a cost-effective treatment. Sativex therefore is not routinely prescribed on the NHS, and can only be prescribed for an individual patient, where local governance and funding arrangements allow for this.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 251364 question first answered 13/05/2019 15:38:24 answering member 4455 label Biography information for Seema Kennedy
tabling member	4425 label Biography information for Jo Stevens

1121479

registered interest
date	11/04/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cannabis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many NHS prescriptions for medicinal cannabis (a) THC and (b) CBD have been issued in England since December 2018.
tabling member constituency	Cardiff Central
tabling member printed	Jo Stevens
uin	244142
answer	answer is ministerial correction date of answer 24/04/2019 answer text <p>NHS England is using extant systems to monitor use of the newly rescheduled unlicensed cannabis-based products for medicinal use in England. In England, these systems monitor the number of items dispensed and associated costs in primary care and the volume of products used and associated cost in secondary care. NHS England Controlled Drug Accountable Officers are also collecting local intelligence in both the National Health Service and independent sector.</p><p>Data on the number of items of cannabis-based medicines dispensed in NHS primary care in England from December 2018 to January 2019 has been published by the NHS Business Services Authority. Such data is published three months in arrears, and we expect information for February 2019 to be published shortly.</p><p>The published data shows that the following number of items of Nabilone and Sativex (two cannabis-based medicines) were dispensed from December 2018 to January 2019:</p><table><tbody><tr><td><p> </p></td><td><p>December 2018</p></td><td><p>January 2019</p></td></tr><tr><td><p>Nabilone</p></td><td><p>49</p></td><td><p>44</p></td></tr><tr><td><p>Sativex</p></td><td><p>181</p></td><td><p>167</p></td></tr></tbody></table><p><strong> </strong></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 24/04/2019 13:15:40 answering member 4455 label Biography information for Seema Kennedy
tabling member	4425 label Biography information for Jo Stevens